DK2290109T3 - Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira - Google Patents

Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira

Info

Publication number
DK2290109T3
DK2290109T3 DK10181786.4T DK10181786T DK2290109T3 DK 2290109 T3 DK2290109 T3 DK 2290109T3 DK 10181786 T DK10181786 T DK 10181786T DK 2290109 T3 DK2290109 T3 DK 2290109T3
Authority
DK
Denmark
Prior art keywords
dengue viruses
attenuation
development
well
chimeric
Prior art date
Application number
DK10181786.4T
Other languages
Danish (da)
English (en)
Inventor
Joseph E Blaney Jr
Ching-Juh Lai
Stephen S Whitehead
Brian R Murphy
Kathryn A Hanley
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of DK2290109T3 publication Critical patent/DK2290109T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5252Virus inactivated (killed)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/295Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151Methods of production or purification of viral material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161Methods of inactivation or attenuation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161Methods of inactivation or attenuation
    • C12N2770/24162Methods of inactivation or attenuation by genetic engineering
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161Methods of inactivation or attenuation
    • C12N2770/24163Methods of inactivation or attenuation by chemical treatment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171Demonstrated in vivo effect
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08RNA viruses
    • G01N2333/18Togaviridae; Flaviviridae
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
DK10181786.4T 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira DK2290109T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29304901P 2001-05-22 2001-05-22
EP02739358A EP1402075B1 (en) 2001-05-22 2002-05-22 Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses

Publications (1)

Publication Number Publication Date
DK2290109T3 true DK2290109T3 (da) 2014-11-10

Family

ID=23127420

Family Applications (4)

Application Number Title Priority Date Filing Date
DK10181804.5T DK2292802T3 (en) 2001-05-22 2002-05-22 Development of mutations useful for attenuation of dengue viruses and chimeric dengue viruses
DK10181776.5T DK2290108T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira, samt kimære dengue-vira
DK02739358.6T DK1402075T3 (da) 2001-05-22 2002-05-22 Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira
DK10181786.4T DK2290109T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira

Family Applications Before (3)

Application Number Title Priority Date Filing Date
DK10181804.5T DK2292802T3 (en) 2001-05-22 2002-05-22 Development of mutations useful for attenuation of dengue viruses and chimeric dengue viruses
DK10181776.5T DK2290108T3 (da) 2001-05-22 2002-05-22 Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira, samt kimære dengue-vira
DK02739358.6T DK1402075T3 (da) 2001-05-22 2002-05-22 Udvikling af egnede mutationer til svækkelse af dengue-vira samt kimære dengue-vira

Country Status (8)

Country Link
US (10) US7226602B2 (pt)
EP (5) EP2292802B1 (pt)
AU (2) AU2002312011B2 (pt)
BR (2) BR122019026154B8 (pt)
CA (5) CA3060687C (pt)
DK (4) DK2292802T3 (pt)
ES (4) ES2533085T3 (pt)
WO (1) WO2002095075A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003092592A2 (en) 2002-05-03 2003-11-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
WO2006036233A1 (en) * 2004-06-14 2006-04-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services West nile viruses with mutations in the 3’ terminal stem and loop secondary structure for use as live virus vaccines
ES2478303T3 (es) 2005-04-24 2014-07-21 Sanofi Pasteur Biologics, Llc Vacunas de flavivirus recombinantes
MX2007015873A (es) 2005-06-17 2008-04-22 Sanofi Pasteur Cepa atenuada de virus de dengue serotipo 1.
BRPI0613287A2 (pt) * 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
CU23578A1 (es) * 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
WO2008157136A1 (en) * 2007-06-14 2008-12-24 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Chimeric sle/dengue type 4 antigenic viruses
MX2010008799A (es) 2008-03-05 2010-09-07 Sanofi Pasteur Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
EP2294192A4 (en) * 2008-06-09 2011-11-23 Jolla Inst Allergy Immunolog COMPOSITIONS AND METHODS OF TREATMENT AND VACCINATION AGAINST DENGUE VIRUS (DV)
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
WO2010094663A1 (en) 2009-02-17 2010-08-26 Glaxosmithkline Biologicals S.A. Inactivated dengue virus vaccine with aluminium-free adjuvant
CA2760348C (en) * 2009-05-12 2017-10-03 Tibotec Pharmaceuticals Method for identifying inhibitors against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
WO2010141386A1 (en) 2009-06-01 2010-12-09 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
CA2803014C (en) * 2009-06-17 2019-03-19 Stephen Woodford Determining haemodynamic performance
JP6057460B2 (ja) 2009-08-31 2017-01-11 ジェン−プローブ・インコーポレーテッド デングウイルスアッセイ
EP2353609A1 (en) 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US10308689B2 (en) 2010-06-24 2019-06-04 La Jolla Institute For Allergy And Immunology Dengue virus (DV) polypeptide sequences, T cell epitopes and methods and uses thereof
US8895028B2 (en) 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
EP3932422A1 (en) 2012-07-24 2022-01-05 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
WO2014204892A1 (en) 2013-06-21 2014-12-24 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
SG11201606624WA (en) 2014-02-11 2016-09-29 Visterra Inc Antibody moleules to dengue virus and uses thereof
EP3189136A4 (en) * 2014-09-05 2018-04-04 The Research Foundation for The State University of New York Recoded arbovirus and vaccines
CR20170280A (es) 2014-12-22 2017-08-21 Merck Sharp & Dohme Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
EP3245306A4 (en) * 2015-01-16 2018-09-05 Takeda Vaccines, Inc. Detection of particle-contained reverse transcriptase activity
WO2017023839A1 (en) 2015-08-03 2017-02-09 The United States Of America As Represented By The Secretary Of The Navy Immune enhancing recombinant dengue protein
WO2017109698A1 (en) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Immunogenic formulation
JP2019511221A (ja) * 2016-03-11 2019-04-25 ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ 弱毒化された生ジカウイルスワクチン
WO2017165736A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulation of antibody molecules to dengue virus
AU2017249510A1 (en) 2016-04-14 2018-12-06 National University Of Singapore Rapid method of generating live attenuated vaccines
WO2018129160A1 (en) 2017-01-06 2018-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live attenuated flavivirus vaccines and methods of using and making same
WO2019069130A1 (en) 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
MX2020005857A (es) 2017-12-07 2020-09-09 Merck Sharp & Dohme Formulaciones de composiciones de vacuna contra el virus del dengue.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6074865A (en) * 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
AU779280B2 (en) * 1999-03-26 2005-01-13 Walter Reed Army Institute Of Research Multivalent dengue virus vaccine
AU4040400A (en) * 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine

Also Published As

Publication number Publication date
US20120114694A1 (en) 2012-05-10
EP1402075A4 (en) 2005-05-11
EP2290109A2 (en) 2011-03-02
BR0209943A (pt) 2004-03-30
US10500264B2 (en) 2019-12-10
US8632782B2 (en) 2014-01-21
ES2533085T3 (es) 2015-04-07
US9707287B2 (en) 2017-07-18
US20200085939A1 (en) 2020-03-19
EP2292802B1 (en) 2015-01-14
EP2940154B1 (en) 2019-05-22
EP1402075A1 (en) 2004-03-31
US20090263424A1 (en) 2009-10-22
ES2399420T3 (es) 2013-04-01
US7226602B2 (en) 2007-06-05
CA3060687C (en) 2021-05-04
CA2448329A1 (en) 2002-11-28
CA3114957A1 (en) 2002-11-28
CA3114957C (en) 2022-02-08
USRE45016E1 (en) 2014-07-15
EP2290108A3 (en) 2011-03-09
EP2290109B1 (en) 2014-08-13
US20070092534A1 (en) 2007-04-26
WO2002095075A1 (en) 2002-11-28
DK1402075T3 (da) 2013-02-11
EP2940154A1 (en) 2015-11-04
EP2290108B1 (en) 2014-07-23
USRE45123E1 (en) 2014-09-09
USRE45053E1 (en) 2014-07-29
BR122019026154B1 (pt) 2020-11-24
CA3060687A1 (en) 2002-11-28
US20050010043A1 (en) 2005-01-13
ES2512715T3 (es) 2014-10-24
US20150064214A1 (en) 2015-03-05
EP2290109A3 (en) 2011-03-16
ES2523168T3 (es) 2014-11-21
CA2755964A1 (en) 2002-11-28
DK2292802T3 (en) 2015-03-09
AU2002312011B2 (en) 2008-04-24
BR122019026154B8 (pt) 2021-07-27
AU2008203275A1 (en) 2008-08-14
CA2755964C (en) 2017-06-27
CA2966716A1 (en) 2002-11-28
EP2292802A2 (en) 2011-03-09
EP2290108A2 (en) 2011-03-02
US8039003B2 (en) 2011-10-18
AU2008203275B2 (en) 2011-11-10
US20180008693A1 (en) 2018-01-11
EP1402075B1 (en) 2012-11-14
DK2290108T3 (da) 2014-10-20
US11318196B2 (en) 2022-05-03
US7560118B2 (en) 2009-07-14
BRPI0209943B1 (pt) 2020-10-13
BRPI0209943B8 (pt) 2021-05-25
CA2448329C (en) 2011-10-25
CA2966716C (en) 2019-11-26
EP2292802A3 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
DK2290109T3 (da) Udvikling af mutationer, der er anvendelige til svækkelse af dengue-vira samt kimære dengue-vira
DK1448523T3 (da) Heterocycliske forbindelser samt metoder til anvendelse deraf
DK1386921T3 (da) Mellemprodukter til fremstilling af anti-trombotiske 4H-cycolopenta-1,3-dioxol-derivater
DK1661569T3 (da) Forbindelser, der påvirker glucokinase
DE60215848D1 (de) 1,2,4-thiadiazolverbindungen als melanocortinrezeptor-modulatoren
DK1505974T3 (da) Anvendelse af forbindelser, der er effektive som selektive opiatreceptormodulatorer
ATE497953T1 (de) Thiazolderivate als modulatoren des cannabinoidrezeptors
NO20052884D0 (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
DK1296935T3 (da) Fremgangsmåde til fremstilling af substituerede octanoylamider
NO20040632L (no) 2-amino-4,5-trisubstituerte tiazolylderivater.
DK1840125T3 (da) Mellemprodukter til fremstilling af dioxan-2-alkylcarbamater
DE50206722D1 (de) Zusammensetzungen, enthaltend quaternäre Ammoniumverbindungen
DK1401828T3 (da) N-Formylhydroxylaminforbindelser som inhibitorer af PDF
DK1392318T3 (da) 15-keto-prostaglandiner til behandling af lægemiddelinduceret forstoppelse
DE602004014772D1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
DE50205159D1 (de) Zusammensetzungen enthaltend quaternäre Ammoniumverbindungen
DE60202489D1 (de) Lysin enthaltende kautablette
DK1390351T3 (da) Pyrimidinderivater, der er nyttige som selektive COX-2-inhibitorer
DK1511724T3 (da) Fremgangsmåde til fremstilling af thioalkylaminderivater
DK1503995T3 (da) Fremgangsmåde til fremstilling af substituerede phenylsulfonylurinstoffer
DK1373232T3 (da) Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner
DK1281707T3 (da) Fremgangsmåde til fremstilling af 5-substituerede isobenzenfuraner
FR2822882B3 (fr) Menuiserie de type etanche, particulierement pour usage civil
EE05246B1 (et) Fungitsiididena kasutatavad oksasiin(ti)oonhendid
DK1685104T3 (da) Fremgangsmåde til fremstilling af N-substituerede phthalomider